Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease
Anemia, Hemolytic, Autoimmune, Felty Syndrome, Purpura, Thrombocytopenic
About this trial
This is an interventional treatment trial for Anemia, Hemolytic, Autoimmune focused on measuring Felty syndrome, autoimmune hemolytic anemia, autoimmune neutropenia, hematologic disorders, immune thrombocytopenic purpura, rare disease
Eligibility Criteria
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Diagnosis of severe autoimmune hematologic disease Autoimmune hemolytic anemia OR Immune thrombocytopenia Failure of at least 2 standard treatment approaches (e.g., prednisone therapy, splenectomy, intravenous immunoglobulin, or other immunosuppressants) Inability to taper prednisone dose to less than 10 mg/day OR Autoimmune neutropenia including the following: Felty's syndrome OR Disorders of large granular lymphocytes with recurrent infections or absolute neutrophil count less than 200/mm3 --Prior/Concurrent Therapy-- See Disease Characteristics --Patient Characteristics-- Age: Not specified Performance status: Not specified Hematopoietic: See Disease Characteristics Hepatic: Not specified Renal: Creatinine no greater than 2.5 mg/dL Cardiovascular: Ejection fraction at least 40% Pulmonary: FVC, FEV1, or DLCO at least 50% predicted Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception Not preterminal or moribund
Sites / Locations
- Johns Hopkins Oncology Center